Retina

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared with unimodal models.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

The drug was previously approved for high blood pressure in 1955.

Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda Light Delivery System (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.

Topline results from the MAGNIFY phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

Dilsher Dhoot, MD, FASRS, shares his forward-looking perspective on developments in retinal disease management, highlighting both recent breakthroughs and promising innovations on the horizon.

As a retinal expert, Ferrucci discusses some emerging retinal therapies that excite him.

With the acquisition, Topcon Healthcare also assumes RetInSight’s AI algorithms that analyze retinal images to detect and monitor disease.

The company said it will be available on the US market for use in clinics and healthcare institutions.

The optimal triple-carotenoid supports daily eye health with lutein, zeaxanthin, and meso-zeaxanthin, according to the company.

The starry faculty has a galaxy of symposia planned for May 4, 2025.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.

CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, lectured on retinal updates at CRU 2025. The pair also covered the power of a low vision referral for patients with retinal disease.

Good safety profile and “meaningful improvement” in vision in patient with Leber congenital amaurosis.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

Management strategies for patients with ocular syphilis primarily involve antibiotic treatment achieved using high-dose intravenous or intramuscular penicillin.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

CRU Cofounder John Gelles, OD, gives his first impressions on how the conference is going thus far in Napa, California.

Researchers developed eye drop formulations 17-mer and H105A, both containing a short peptide, to administer to mice in the form of a drop on the eye’s surface.